Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: onr:"swepub:oai:gup.ub.gu.se/331164" > Ki67 and prostate s...

1 of 1
Previous record
Next record
To hitlist

Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer

Spyratou, Vasiliki, 1981 (author): Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology,Department of Urology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden

Freyhult, Eva, 1979- (author): Uppsala universitet,Beräkningsbiologi och bioinformatik,Science for Life Laboratory, SciLifeLab,National Bioinformatics Infrastructure Sweden (NBIS)

Bergh, Anders (author): Umeå universitet,Patologi

Thellenberg-Karlsson, Camilla, 1972- (author): Umeå universitet,Onkologi

Wikström, Pernilla (author): Umeå universitet,Patologi

Welén, Karin, 1970 (author): Gothenburg University,Göteborgs universitet,Sahlgrenska Centrum för Cancerforskning (SCCR),Institutionen för kliniska vetenskaper, Avdelningen för urologi,Sahlgrenska Center for Cancer Research (SCCR),Institute of Clinical Sciences, Department of Urology,Department of Urology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; Sahlgrenska Center for Cancer Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Josefsson, Andreas, 1979- (author): Umeå universitet,Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för urologi,Institute of Clinical Sciences, Department of Urology,Wallenberg centrum för molekylär medicin vid Umeå universitet (WCMM),Urologi och andrologi,Department of Urology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden

show less...

(creator_code:org_t)

Taylor & Francis, 2023
2023
English.
In: Acta Oncologica. - : Taylor & Francis. - 0284-186X .- 1651-226X. ; 62:12, s. 1698-1706

Related links:: https://doi.org/10.1...; show more...; https://umu.diva-por... (primary) (Raw object); https://uu.diva-port... (primary) (Raw object); https://gup.ub.gu.se...; https://doi.org/10.1...; https://urn.kb.se/re...; https://urn.kb.se/re...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

Background: For metastatic hormone naïve prostate cancer patients, androgen deprivation therapy (ADT) with escalation therapy including docetaxel and/or androgen targeting drugs is the standard therapy. However, de-escalation is preferable to avoid unnecessary side effects, especially from docetaxel, but markers to identify these patients are lacking. The purpose of the present study was to investigate the potential of PSA and Ki67 immunoreactive scores as prognostic and treatment-predictive markers. Material and methods: Prostate biopsies from 92 patients with metastatic hormone naïve PC (PSA > 80 ng/mL or clinical metastases) were immunohistochemically evaluated for PSA and Ki67. Gene expression analysis was performed with Clariom D microarrays to identify the phenotypic profile associated with the immunohistochemistry scores of biopsies. Cox regression analysis for progression free survival after ADT adjustment for age, ISUP, and serum PSA and Kaplan-Meier analyses were performed to assess prognostic values of Ki67, PSA, and the Ki67/PSA ratio. Results: The immunohistochemical score for PSA was the strongest prognostic factor for progression-free and overall survival after ADT. Consequently, the ratio between Ki67 and PSA displayed a stronger prognostic value than Ki67 itself. Further, mRNA expression data analysis showed an association between high Ki67/PSA ratio, cell-cycle regulation, and DNA damage repair. In an exploratory sub-analysis of 12 patients treated with early docetaxel as addition to ADT and matched controls, a high Ki67/PSA ratio showed potential to identify those who benefit from docetaxel. Conclusion: PSA and Ki67 immunoreactive scores are prognostic in the metastatic hormone-sensitive setting, with PSA being superior. The combination of Ki67 and PSA did not give additional prognostic value. The results suggest immunohistochemical scoring of PSA to have potential to improve identification of patients responding well to ADT alone.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Urologi och njurmedicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Urology and Nephrology (hsv//eng)

Keyword

androgen deprivation therapy
biomarker
docetaxel
Metastatic prostate cancer
prostate specific antigen
androgen deprivation therapy

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

Acta Oncologica (Search for host publication in LIBRIS)

To the university's database

1 of 1
Previous record
Next record
To hitlist

Find more in SwePub

By the author/editor: Spyratou, Vasili ...; Freyhult, Eva, 1 ...; Bergh, Anders; Thellenberg-Karl ...; Wikström, Pernil ...; Welén, Karin, 19 ...; show more...; Josefsson, Andre ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Cancer and Oncol ...

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Urology and Neph ...

Articles in the publication: Acta Oncologica

By the university: University of Gothenburg; Umeå University; Uppsala University

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se